

Diabetic Foot Ulcers Market Report and Forecast 2024-2032

Market Report (7 days) | 2024-02-09 | 140 pages | EMR Inc.

AVAILABLE LICENSES:

- Single User License \$5499.00
- Five User License \$7499.00
- Corporate License \$9499.00

Report description:

Diabetic Foot Ulcers Market Report and Forecast 2024-2032

Diabetic Foot Ulcers Market Outlook

The diabetic foot ulcers market size was valued at USD 6.32 billion in 2023, driven by increasing prevalence of diabetes. The market size is anticipated to grow at a CAGR of 5.85% during the forecast period of 2024-2032 to achieve a value of USD 10.5 billion by 2032.

Diabetic Foot Ulcers: Introduction

Diabetic foot ulcers are open sores or wounds that occur in approximately 15% of patients with diabetes and commonly develop on the bottom of the foot. They are a major complication of diabetes, resulting from a combination of factors, including poor circulation, neuropathy (nerve damage), foot deformities, and pressure or friction. These ulcers can become serious if not treated promptly, as they may lead to infections and, in severe cases, amputation.

Key Trends in the Diabetic Foot Ulcers Market

Globally, the increasing prevalence of diabetes due to sedentary lifestyles, obesity, and aging populations is leading to a higher incidence of diabetic foot ulcers. This trend is prompting a growing demand for effective treatment options and is driving research and development in this field.

There is a significant trend towards the adoption of advanced wound care products, including biologics, skin substitutes, and advanced dressings. These technologies are designed to promote faster healing, reduce the risk of infection, and improve patient outcomes.

There's an increasing emphasis on a multidisciplinary approach to diabetic foot ulcer management, involving specialists such as diabetologists, podiatrists, wound care experts, and nutritionists. This comprehensive care model aims to address all aspects of the condition, from blood sugar control to local wound care.

The demand for home healthcare services for diabetic foot ulcer treatment is growing, driven by patient preference for receiving care in the comfort of their homes. Home healthcare is also seen as a cost-effective alternative to hospital stays.

Telemedicine and remote monitoring are becoming increasingly important in managing diabetic foot ulcers, especially in rural or underserved areas. These technologies allow for regular monitoring of ulcers, timely intervention, and better patient education, improving overall patient management.

Governments and non-governmental organizations worldwide are initiating programs to raise awareness about diabetes and its complications, including diabetic foot ulcers. These initiatives often provide education, resources, and support to improve prevention, early detection, and management of diabetic foot ulcers.

Diabetic Foot Ulcers Market Segmentation

Market Breakup by Product Type

- -□Biologics
- -□Wound Care Dressings

Market Breakup by Type

- Neuro-ischemic
- -∏Ischemic
- Neuropathic
- -∏Others

Market Breakup by Route of Administration

- -∏Oral
- Parenteral
- -[Others

Market Breakup by End User

- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy

Market Breakup by Region

- -□United States
- -∏EU-4 and the United Kingdom
- o∏Germany
- o∏France
- o∏Italy
- o∏Spain
- o∏United Kingdom
- -∐apan

Diabetic Foot Ulcers Market Overview

North America, particularly the United States, shows a proactive approach to DFU management, marked by advanced healthcare facilities, a high standard of care, and significant investments in research and development. There is a strong emphasis on early detection and comprehensive treatment, including innovative wound care products and therapies. Public awareness campaigns and diabetes education programs also contribute to market dynamics.

Europe demonstrates a strong commitment to diabetes management and DFU treatment, supported by well-established healthcare systems and public health initiatives. The region sees a steady adoption of advanced wound care products, driven by a focus on reducing hospital stays and promoting cost-effective treatment options. European countries also have stringent regulations ensuring the quality and efficacy of medical products, influencing the DFU market landscape.

Japan is experiencing rapid growth in the DFU market, propelled by a rising diabetic population, increasing healthcare expenditure, and growing awareness of advanced wound care solutions. Countries like China, India, and Japan are investing in healthcare infrastructure improvement and diabetes management programs. However, there is considerable variation in access to advanced DFU treatments across different countries in the region.

Diabetic Foot Ulcers Market: Competitor Landscape

The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players.

- -□ConvaTec, Inc.
- □ Acelity L.P., Inc

Scotts International, EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- -∏3M Healthcare
- -□Coloplast Corp.
- -□Smith & Nephew Plc
- -□B Braun Melsungen AG
- -□Medline Industries, Inc.
- -□Organogenesis, Inc.
- Molnlycke Health Care AB
- -[Kerecis
- -∏Essity Aktiebolag AB
- -∏Tissue Regenix
- -∏Integra Lifesciences
- ¬Cardinal Health

We at Expert Market Research always strive to provide you with the latest information. The numbers in the article are only indicative and may be different from the actual report.

Table of Contents:

- 1 Preface
 - 1.1 Objectives of the Study
 - 1.2 Key Assumptions
 - 1.3 Report Coverage Key Segmentation and Scope
 - 1.4 Research Methodology
- 2 Executive Summary
- 3 Diabetic Foot Ulcers Overview
 - 3.1 Guidelines and Stages
 - 3.2 Pathophysiology
 - 3.3 Screening and Diagnosis
 - 3.4 Treatment Pathway
- 4 Patient Profile
 - 4.1 Patient Profile Overview
 - 4.2 Patient Psychology and Emotional Impact Factors
 - 4.3 Risk Assessment and Treatment Success Rate
- 5 Diabetic Foot Ulcers Epidemiology Analysis 7MM
 - 5.1 7MM Epidemiology Scenario Overview (2017-2032)
 - 5.2 United States Diabetic Foot Ulcers Epidemiology Forecast (2017-2032)
 - 5.3 EU-4 and United Kingdom Diabetic Foot Ulcers Epidemiology Forecast (2017-2032)
 - 5.3.1 Germany Diabetic Foot Ulcers Epidemiology Forecast (2017-2032)
 - 5.3.2 France Diabetic Foot Ulcers Epidemiology Forecast (2017-2032)
 - 5.3.3 Italy Diabetic Foot Ulcers Epidemiology Forecast (2017-2032)
 - 5.3.4 Spain Diabetic Foot Ulcers Epidemiology Forecast (2017-2032)
 - 5.3.5 United Kingdom Diabetic Foot Ulcers Epidemiology Forecast (2017-2032)
 - 5.4 Japan Diabetic Foot Ulcers Epidemiology Forecast (2017-2032)
- 6 Diabetic Foot Ulcers Market Overview 7MM
 - 6.1 Diabetic Foot Ulcers Market Historical Value (2017-2023)

Scotts International, EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

6.2 Diabetic Foot Ulcers Market Forecast Value (2024-2032)

- 7 Diabetic Foot Ulcers Market Landscape 7MM
 - 7.1 Diabetic Foot Ulcers Developers Landscape
 - 7.1.1 Analysis by Year of Establishment
 - 7.1.2 Analysis by Company Size
 - 7.1.3 Analysis by Region
 - 7.2 Diabetic Foot Ulcers Product Landscape
 - 7.2.1 Analysis by Products
 - 7.2.2 Analysis by Type
 - 7.2.3 Analysis by Route of Administration
- 8 Diabetic Foot Ulcers Challenges and Unmet Needs
 - 8.1 Treatment Pathway Challenges
 - 8.2 Compliance and Drop-Out Analysis
 - 8.3 Awareness and Prevention Gaps
- 9 Cost of Treatment
- 10 Diabetic Foot Ulcers Market Dynamics
 - 10.1 Market Drivers and Constraints
 - 10.2 SWOT Analysis
 - 10.3 Porter's Five Forces Model
 - 10.4 Key Demand Indicators
 - 10.5 Key Price Indicators
 - 10.6 Industry Events, Initiatives, and Trends
 - 10.7 Value Chain Analysis
- 11 Diabetic Foot Ulcers Market Segmentation 7MM
 - 11.1 Diabetic Foot Ulcers Market by Product Type
 - 11.1.1 Market Overview
 - 11.1.2 Biologics
 - 11.1.3 Wound Care Dressings
 - 11.2 Diabetic Foot Ulcers Market by Type
 - 11.2.1 Market Overview
 - 11.2.2 Neuro-ischemic
 - 11.2.3 Ischemic
 - 11.2.4 Neuropathic
 - 11.2.5 Others
 - 11.3 Diabetic Foot Ulcers Market by Route of Administration
 - 11.3.1 Market Overview
 - 11.3.2 Oral
 - 11.3.3 Parenteral
 - 11.3.4 Others
 - 11.4 Diabetic Foot Ulcers Market by End User
 - 11.4.1 Market Overview
 - 11.4.2 Hospital Pharmacy
 - 11.4.3 Online Pharmacy
 - 11.4.4 Retail Pharmacy
 - 11.5 Diabetic Foot Ulcers Market by Region
 - 11.5.1 Market Overview
 - 11.5.2 United States

Scotts International. EU Vat number: PL 6772247784

11.5.3 EU-4 and the United Kingdom

- 11.5.3.1 Germany
- 11.5.3.2 France
- 11.5.3.3 Italy
- 11.5.3.4 Spain
- 11.5.3.5 United Kingdom
- 11.5.4 Japan

12 United States Diabetic Foot Ulcers Market

- 12.1 Diabetic Foot Ulcers Market Historical Value (2017-2023)
- 12.2 Diabetic Foot Ulcers Market Forecast Value (2024-2032)
- 12.3 Diabetic Foot Ulcers Market by Disease Type
- 12.4 Diabetic Foot Ulcers Market by Treatment Type
- 13 EU-4 and United Kingdom Diabetic Foot Ulcers Market
 - 13.1 Diabetic Foot Ulcers Market Historical Value (2017-2023)
 - 13.2 Diabetic Foot Ulcers Market Forecast Value (2024-2032)
 - 13.3 Germany Diabetic Foot Ulcers Market Overview
 - 13.3.1 Diabetic Foot Ulcers Market by Disease Type
 - 13.3.2 Diabetic Foot Ulcers Market by Treatment Type
 - 13.4 France Diabetic Foot Ulcers Market Overview
 - 13.4.1 Diabetic Foot Ulcers Market by Disease Type
 - 13.4.2 Diabetic Foot Ulcers Market by Treatment Type
 - 13.5 Italy Diabetic Foot Ulcers Market Overview
 - 13.5.1 Diabetic Foot Ulcers Market by Disease Type
 - 13.5.2 Diabetic Foot Ulcers Market by Treatment Type
 - 13.6 Spain Diabetic Foot Ulcers Market Overview
 - 13.6.1 Diabetic Foot Ulcers Market by Disease Type
 - 13.6.2 Diabetic Foot Ulcers Market by Treatment Type
 - 13.7 United Kingdom Diabetic Foot Ulcers Market Overview
 - 13.7.1 Diabetic Foot Ulcers Market by Disease Type
 - 13.7.2 Diabetic Foot Ulcers Market by Treatment Type
- 14 Japan Diabetic Foot Ulcers Market
 - 14.1 Diabetic Foot Ulcers Market Historical Value (2017-2023)
 - 14.2 Diabetic Foot Ulcers Market Forecast Value (2024-2032)
 - 14.3 Diabetic Foot Ulcers Market by Disease Type
 - 14.4 Diabetic Foot Ulcers Market by Treatment Type
- 15 Patent Analysis
 - 15.1 Analysis by Type of Patent
 - 15.2 Analysis by Publication year
 - 15.3 Analysis by Issuing Authority
 - 15.4 Analysis by Patent Age
 - 15.5 Analysis by CPC Analysis
 - 15.6 Analysis by Patent Valuation
 - 15.7 Analysis by Key Players
- 16 Grants Analysis
 - 16.1 Analysis by year
 - 16.2 Analysis by Amount Awarded
 - 16.3 Analysis by Issuing Authority

Scotts International. EU Vat number: PL 6772247784

- 16.4 Analysis by Grant Application
- 16.5 Analysis by Funding Institute
- 16.6 Analysis by NIH Departments
- 16.7 Analysis by Recipient Organization
- 17 Clinical Trials Analysis
 - 17.1 Analysis by Trial Registration Year
 - 17.2 Analysis by Trial Status
 - 17.3 Analysis by Trial Phase
 - 17.4 Analysis by Therapeutic Area
 - 17.5 Analysis by Geography
- 18 Funding Analysis
 - 18.1 Analysis by Funding Instances
 - 18.2 Analysis by Type of Funding
 - 18.3 Analysis by Funding Amount
 - 18.4 Analysis by Leading Players
 - 18.5 Analysis by Leading Investors
 - 18.6 Analysis by Geography
- 19 Partnership and Collaborations Analysis
 - 19.1 Analysis by Partnership Instances
 - 19.2 Analysis by Type of Partnership
 - 19.3 Analysis by Leading Players
 - 19.4 Analysis by Geography
- 20 Supplier Landscape
 - 20.1 ConvaTec, Inc.
 - 20.1.1 Financial Analysis
 - 20.1.2 Product Portfolio
 - 20.1.3 Demographic Reach and Achievements
 - 20.1.4 Mergers and Acquisition
 - 20.1.5 Certifications
 - 20.2 Acelity L.P., Inc
 - 20.2.1 Financial Analysis
 - 20.2.2 Product Portfolio
 - 20.2.3 Demographic Reach and Achievements
 - 20.2.4 Mergers and Acquisition
 - 20.2.5 Certifications
 - 20.3 3M Healthcare
 - 20.3.1 Financial Analysis
 - 20.3.2 Product Portfolio
 - 20.3.3 Demographic Reach and Achievements
 - 20.3.4 Mergers and Acquisition
 - 20.3.5 Certifications
 - 20.4 Coloplast Corp.
 - 20.4.1 Financial Analysis
 - 20.4.2 Product Portfolio
 - 20.4.3 Demographic Reach and Achievements
 - 20.4.4 Mergers and Acquisition
 - 20.4.5 Certifications

Scotts International. EU Vat number: PL 6772247784

20.5 Smith & Nephew Plc 20.5.1 Financial Analysis 20.5.2 Product Portfolio 20.5.5 Certifications

- 20.5.3 Demographic Reach and Achievements
- 20.5.4 Mergers and Acquisition
- 20.6 B Braun Melsungen AG
 - 20.6.1 Financial Analysis
 - 20.6.2 Product Portfolio
 - 20.6.3 Demographic Reach and Achievements
 - 20.6.4 Mergers and Acquisition
 - 20.6.5 Certifications
- 20.7 Medline Industries, Inc.
 - 20.7.1 Financial Analysis
 - 20.7.2 Product Portfolio
 - 20.7.3 Demographic Reach and Achievements
 - 20.7.4 Mergers and Acquisition
 - 20.7.5 Certifications
- 20.8 Organogenesis, Inc.
 - 20.8.1 Financial Analysis
 - 20.8.2 Product Portfolio
 - 20.8.3 Demographic Reach and Achievements
 - 20.8.4 Mergers and Acquisition
 - 20.8.5 Certifications
- 20.9 Molnlycke Health Care AB
 - 20.9.1 Financial Analysis
 - 20.9.2 Product Portfolio
 - 20.9.3 Demographic Reach and Achievements
 - 20.9.4 Mergers and Acquisition
 - 20.9.5 Certifications
- 20.10 Medtronics
 - 20.10.1 Financial Analysis
 - 20.10.2 Product Portfolio
 - 20.10.3 Demographic Reach and Achievements
 - 20.10.4 Mergers and Acquisition
 - 20.10.5 Certifications
- 20.11 Kerecis
 - 20.11.1 Financial Analysis
 - 20.11.2 Product Portfolio
 - 20.11.3 Demographic Reach and Achievements
 - 20.11.4 Mergers and Acquisition
 - 20.11.5 Certifications
- 20.12 Essity Aktiebolag AB
 - 20.12.1 Financial Analysis
 - 20.12.2 Product Portfolio
 - 20.12.3 Demographic Reach and Achievements
 - 20.12.4 Mergers and Acquisition

Scotts International, EU Vat number: PL 6772247784

20.12.5 Certifications

- 20.13 Tissue Regenix
 - 20.13.1 Financial Analysis
 - 20.13.2 Product Portfolio
 - 20.13.3 Demographic Reach and Achievements
 - 20.13.4 Mergers and Acquisition
 - 20.13.5 Certifications
- 20.14 Integra Lifesciences
 - 20.14.1 Financial Analysis
 - 20.14.2 Product Portfolio
 - 20.14.3 Demographic Reach and Achievements
 - 20.14.4 Mergers and Acquisition
 - 20.14.5 Certifications
- 20.15 Cardinal Health
 - 20.15.1 Financial Analysis
 - 20.15.2 Product Portfolio
 - 20.15.3 Demographic Reach and Achievements
 - 20.15.4 Mergers and Acquisition
 - 20.15.5 Certifications
- 21 Diabetic Foot Ulcers Market Distribution Model (Additional Insight)
 - 21.1 Overview
 - 21.2 Potential Distributors
 - 21.3 Key Parameters for Distribution Partner Assessment
- 22 Key Opinion Leaders (KOL) Insights (Additional Insight)
- 23 Company Competitiveness Analysis (Additional Insight)
 - 23.1 Very Small Companies
 - 23.2 Small Companies
 - 23.3 Mid-Sized Companies
 - 23.4 Large Companies
 - 23.5 Very Large Companies
- 24 Payment Methods (Additional Insight)
 - 24.1 Government Funded
 - 24.2 Private Insurance
 - 24.3 Out-of-Pocket

Scotts International. EU Vat number: PL 6772247784

^{*}Additional insights provided are customisable as per client requirements.



☐ - Print this form

To place an Order with Scotts International:

 $\hfill \Box$ - Complete the relevant blank fields and sign

Diabetic Foot Ulcers Market Report and Forecast 2024-2032

Market Report (7 days) | 2024-02-09 | 140 pages | EMR Inc.

Five User License 5	Select license	License			Price
Corporate License VAT Total Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 *VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a value. Email* Phone* Last Name* ob title*		Single User License			\$5499.00
Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 ** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a value of the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 ** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a value of the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 ** Table 1		Five User License			\$7499.00
Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 ** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a value of the provide and		Corporate License			\$9499.00
Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 ** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a value of the provide a value of the provide and EU based companies who are unable to provide a value of the provide a valu					VAT
** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a value of the provi					Total
b title* Last Name* Last Name*					
irst Name* Last Name* bb title*					
ob title*	mail*		Phone*		
ompany Name* EU Vat / Tax ID / NIP number*	irst Name*		Last Name*		
			Last Name*		
ddress* City*	ob title*) / NIP number*	
Zip Code* Country*	ob title* Company Name*		EU Vat / Tax ID) / NIP number*	
Date 2025-05-06	ob title*		EU Vat / Tax ID) / NIP number*	
	ob title* Company Name* Address*		EU Vat / Tax ID City* Country*		

Scotts International. EU Vat number: PL 6772247784